These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 23879463)

  • 21. DOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated leukemogenesis.
    Nguyen AT; Taranova O; He J; Zhang Y
    Blood; 2011 Jun; 117(25):6912-22. PubMed ID: 21521783
    [TBL] [Abstract][Full Text] [Related]  

  • 22. DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia.
    Rau RE; Rodriguez BA; Luo M; Jeong M; Rosen A; Rogers JH; Campbell CT; Daigle SR; Deng L; Song Y; Sweet S; Chevassut T; Andreeff M; Kornblau SM; Li W; Goodell MA
    Blood; 2016 Aug; 128(7):971-81. PubMed ID: 27335278
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The histone H3K79 methyltransferase Dot1L is essential for mammalian development and heterochromatin structure.
    Jones B; Su H; Bhat A; Lei H; Bajko J; Hevi S; Baltus GA; Kadam S; Zhai H; Valdez R; Gonzalo S; Zhang Y; Li E; Chen T
    PLoS Genet; 2008 Sep; 4(9):e1000190. PubMed ID: 18787701
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Deficiency of H3K79 histone methyltransferase Dot1-like protein (DOT1L) inhibits cell proliferation.
    Kim W; Kim R; Park G; Park JW; Kim JE
    J Biol Chem; 2012 Feb; 287(8):5588-99. PubMed ID: 22190683
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Degree of recruitment of DOT1L to MLL-AF9 defines level of H3K79 Di- and tri-methylation on target genes and transformation potential.
    Kuntimaddi A; Achille NJ; Thorpe J; Lokken AA; Singh R; Hemenway CS; Adli M; Zeleznik-Le NJ; Bushweller JH
    Cell Rep; 2015 May; 11(5):808-20. PubMed ID: 25921540
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Perturbation of Methionine/S-adenosylmethionine Metabolism as a Novel Vulnerability in MLL Rearranged Leukemia.
    Barve A; Vega A; Shah PP; Ghare S; Casson L; Wunderlich M; Siskind LJ; Beverly LJ
    Cells; 2019 Oct; 8(11):. PubMed ID: 31717699
    [TBL] [Abstract][Full Text] [Related]  

  • 27. DOT1L and H3K79 Methylation in Transcription and Genomic Stability.
    Wood K; Tellier M; Murphy S
    Biomolecules; 2018 Feb; 8(1):. PubMed ID: 29495487
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia.
    Dafflon C; Craig VJ; Méreau H; Gräsel J; Schacher Engstler B; Hoffman G; Nigsch F; Gaulis S; Barys L; Ito M; Aguadé-Gorgorió J; Bornhauser B; Bourquin JP; Proske A; Stork-Fux C; Murakami M; Sellers WR; Hofmann F; Schwaller J; Tiedt R
    Leukemia; 2017 Jun; 31(6):1269-1277. PubMed ID: 27840424
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dot1L mediated histone H3 lysine79 methylation is essential to meiosis progression in mouse oocytes.
    Wang X; Gao W; Ma X; Wang X; Song C; Huang X; Liu H
    Neuro Endocrinol Lett; 2014; 35(6):523-30. PubMed ID: 25433842
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Potent inhibition of DOT1L as treatment of MLL-fusion leukemia.
    Daigle SR; Olhava EJ; Therkelsen CA; Basavapathruni A; Jin L; Boriack-Sjodin PA; Allain CJ; Klaus CR; Raimondi A; Scott MP; Waters NJ; Chesworth R; Moyer MP; Copeland RA; Richon VM; Pollock RM
    Blood; 2013 Aug; 122(6):1017-25. PubMed ID: 23801631
    [TBL] [Abstract][Full Text] [Related]  

  • 31. DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia.
    Chen CW; Koche RP; Sinha AU; Deshpande AJ; Zhu N; Eng R; Doench JG; Xu H; Chu SH; Qi J; Wang X; Delaney C; Bernt KM; Root DE; Hahn WC; Bradner JE; Armstrong SA
    Nat Med; 2015 Apr; 21(4):335-43. PubMed ID: 25822366
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery of potent DOT1L inhibitors by AlphaLISA based High Throughput Screening assay.
    Song Y; Li L; Chen Y; Liu J; Xiao S; Lian F; Zhang N; Ding H; Zhang Y; Chen K; Jiang H; Zhang C; Liu YC; Chen S; Luo C
    Bioorg Med Chem; 2018 May; 26(8):1751-1758. PubMed ID: 29534934
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The histone methyltransferase Dot1/DOT1L as a critical regulator of the cell cycle.
    Kim W; Choi M; Kim JE
    Cell Cycle; 2014; 13(5):726-38. PubMed ID: 24526115
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exploring drug delivery for the DOT1L inhibitor pinometostat (EPZ-5676): Subcutaneous administration as an alternative to continuous IV infusion, in the pursuit of an epigenetic target.
    Waters NJ; Daigle SR; Rehlaender BN; Basavapathruni A; Campbell CT; Jensen TB; Truitt BF; Olhava EJ; Pollock RM; Stickland KA; Dovletoglou A
    J Control Release; 2015 Dec; 220(Pt B):758-65. PubMed ID: 26385168
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Histone H2B ubiquitin ligase RNF20 is required for MLL-rearranged leukemia.
    Wang E; Kawaoka S; Yu M; Shi J; Ni T; Yang W; Zhu J; Roeder RG; Vakoc CR
    Proc Natl Acad Sci U S A; 2013 Mar; 110(10):3901-6. PubMed ID: 23412334
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthesis and Biological Activity of a Cytostatic Inhibitor of MLLr Leukemia Targeting the DOT1L Protein.
    Bon C; Si Y; Pernak M; Barbachowska M; Levi-Acobas E; Cadet Daniel V; Jallet C; Ruzic D; Djokovic N; Djikić T; Nikolic K; Halby L; Arimondo PB
    Molecules; 2021 Aug; 26(17):. PubMed ID: 34500733
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery of Novel Dot1L Inhibitors through a Structure-Based Fragmentation Approach.
    Chen C; Zhu H; Stauffer F; Caravatti G; Vollmer S; Machauer R; Holzer P; Möbitz H; Scheufler C; Klumpp M; Tiedt R; Beyer KS; Calkins K; Guthy D; Kiffe M; Zhang J; Gaul C
    ACS Med Chem Lett; 2016 Aug; 7(8):735-40. PubMed ID: 27563395
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting DOT1L and HOX gene expression in MLL-rearranged leukemia and beyond.
    Chen CW; Armstrong SA
    Exp Hematol; 2015 Aug; 43(8):673-84. PubMed ID: 26118503
    [TBL] [Abstract][Full Text] [Related]  

  • 39. H3K79 methylation profiles define murine and human MLL-AF4 leukemias.
    Krivtsov AV; Feng Z; Lemieux ME; Faber J; Vempati S; Sinha AU; Xia X; Jesneck J; Bracken AP; Silverman LB; Kutok JL; Kung AL; Armstrong SA
    Cancer Cell; 2008 Nov; 14(5):355-68. PubMed ID: 18977325
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Selective DOT1L, LSD1, and HDAC Class I Inhibitors Reduce HOXA9 Expression in MLL-AF9 Rearranged Leukemia Cells, But Dysregulate the Expression of Many Histone-Modifying Enzymes.
    Lillico R; Lawrence CK; Lakowski TM
    J Proteome Res; 2018 Aug; 17(8):2657-2667. PubMed ID: 29972300
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.